自体 CD19 靶向嵌合抗原受体 (CAR)T 细胞治疗系统性红斑狼疮的未来。
Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.
机构信息
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Udayana University / Prof dr I Goesti Ngoerah Gde Ngoerah General Hospital, Denpasar, Bali, Indonesia.
Department of Internal Medicine, North Lombok Regional Hospital, West Nusa Tenggara, Indonesia.
出版信息
Curr Rheumatol Rev. 2023 Jun 5;19(3):260-269. doi: 10.2174/1573397119666230214103044.
Systemic lupus erythematosus (SLE) is a chronic autoimmune illness with an unclear etiology and a range of clinical manifestations. The therapeutic results of current conventional treatments are frequently unsatisfactory. Many B-cell-directed immunotherapies have recently been discovered, as B cells play a key role in the pathogenesis of SLE. However, large-scale rituximab trials found that the antibody against CD20 was no better than a placebo. Autologous CAR T-cell therapy has garnered considerable interest and is considered a potential treatment option for SLE. CD19+CD20- B cells are thought to play an essential role in the onset and progression of SLE. CD19-targeted CAR T-cells destroy B cells without requiring an accessory cell type, thereby decreasing B cells more efficiently. Preclinical trials of CAR T-cells in mice have shown promising results against SLE. The review aimed to shed light on autologous CD19-targeted CAR T-cells as a potential treatment for SLE.
系统性红斑狼疮（SLE）是一种病因不明、临床表现多样的慢性自身免疫性疾病。目前常规治疗的疗效往往不尽如人意。最近发现了许多针对 B 细胞的免疫疗法，因为 B 细胞在 SLE 的发病机制中起关键作用。然而，大规模的利妥昔单抗试验发现，抗 CD20 抗体并不优于安慰剂。自体嵌合抗原受体 T 细胞（CAR T）疗法引起了广泛关注，被认为是 SLE 的一种潜在治疗选择。CD19+CD20-B 细胞被认为在 SLE 的发病和进展中起重要作用。CD19 靶向 CAR T 细胞无需辅助细胞类型即可破坏 B 细胞，从而更有效地减少 B 细胞。CAR T 细胞在小鼠中的临床前试验显示出对 SLE 有很好的疗效。本综述旨在探讨自体 CD19 靶向 CAR T 细胞作为 SLE 潜在治疗方法的作用。
Zotero 插件